Company Growth (employees)
Sucampo Pharmaceuticals was founded in 1996 and is headquartered in Rockville, US
Sucampo Pharmaceuticals Office Locations
Sucampo Pharmaceuticals has offices in Rockville, Milton, Zug, Kita Ward and in 3 other locations
Rockville, US (HQ)
550 805 King Farm Blvd
Sanda-shi, JP
4-1 Techno-Park
Chuo Ward, JP
Kobe Hybrid Business Center, 3rd Floor 6-7-6 Minatojima Minamimachi, Chuo-ku, Kobe City
Chiyoda, JP
NBF Hibiya Building, 10th Floor 1-1-7 Uchisaiwaicho
Kita Ward, JP
Nishiumeda MID Building, 4th Floor 2-2-16 Sonezakishinchi
Zug, CH
22 Baarerstrasse
Sucampo Pharmaceuticals Data and Metrics
Sucampo Pharmaceuticals Financial Metrics
Sucampo Pharmaceuticals's revenue was reported to be $56.3 m in Q1, 2017
USD
Revenue (Q1, 2017) | 56.3 m |
Gross profit (Q1, 2017) | 39.4 m |
Gross profit margin (Q1, 2017), % | 70% |
Net income (Q1, 2017) | 4.6 m |
EBIT (Q1, 2017) | 10.9 m |
Market capitalization (21-Sep-2017) | 547.4 m |
Cash (31-Mar-2017) | 243.5 m |
Sucampo Pharmaceuticals's current market capitalization is $547.4 m.
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 89.6 m | 115.5 m | 153.2 m | 230.1 m |
Revenue growth, % | 29% | 33% | 50% | |
Cost of goods sold | 12.4 m | 16.3 m | 36.7 m | 76 m |
Gross profit | 77.2 m | 99.2 m | 116.4 m | 154.1 m |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | 24.1 m | 31.5 m | 29.5 m | 34.9 m | 33.4 m | 47.2 m | 52 m | 57.9 m | 56.3 m |
Cost of goods sold | 3.8 m | 5 m | 6.1 m | 7.3 m | 5.3 m | 23.3 m | 20.4 m | 15.6 m | 16.9 m |
Gross profit | 20.3 m | 26.5 m | 23.4 m | 27.6 m | 28.2 m | 23.9 m | 31.6 m | 42.3 m | 39.4 m |
Gross profit Margin, % | 84% | 84% | 79% | 79% | 84% | 51% | 61% | 73% | 70% |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 44.1 m | 71.6 m | 108.3 m | 198.3 m |
Accounts Receivable | 5.4 m | 5.3 m | 22.8 m | 43 m |
Inventories | 4 m | 3.4 m | 8.9 m | 23.5 m |
Current Assets | 113.4 m | 122.3 m | 251.4 m | 307.2 m |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 53.5 m | 56.1 m | 59.6 m | 71.3 m | 91.5 m | 130.1 m | 128 m | 128.5 m | 243.5 m |
Accounts Receivable | 4.8 m | 8.5 m | 8.2 m | 8.2 m | 6.7 m | 16.1 m | 18.2 m | 20.7 m | 20.5 m |
Inventories | 423 k | 133 k | 328 k | 308 k | 296 k | 24.4 m | 21.6 m | 24.2 m | 23 m |
Current Assets | 119.3 m | 124.1 m | 120.9 m | 136.7 m | 161.4 m | 228.1 m | 237.7 m | 237.5 m | 322.4 m |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | 6.4 m | 13.1 m | 33.4 m | 18.5 m |
Depreciation and Amortization | 1.5 m | 10.6 m | 45.7 m | |
Accounts Receivable | (4 m) | (8.5 m) | (18.8 m) | |
Inventories | (163 k) | (1.4 m) | (1.2 m) |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | 1.6 m | 1.5 m | 6.4 m | 9.6 m | 7.2 m | (4.1 m) | (832 k) | 8.1 m | 4.6 m |
Accounts Receivable | 4.8 m | 8.5 m | 8.2 m | 8.2 m | 6.7 m | 16.1 m | 18.2 m | 20.7 m | 20.5 m |
Inventories | 423 k | 133 k | 328 k | 308 k | 296 k | 24.4 m | 21.6 m | 24.2 m | |
Accounts Payable | 5.6 m | 5.9 m | 1.4 m | 3.9 m | 4.9 m | 5.1 m | 6.2 m | 7.9 m | 8 m |
| USD | Y, 2017 |
|---|---|
Revenue/Employee | 404.9 k |
Financial Leverage | 3 x |
